ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Hemophilia Drugs Market Research Report 2025
Published Date: September 2025
|
Report Code: QYRE-Auto-34S10951
Home | Market Reports | Health| Pharmacy| Drugs & Medications
Global Hemophilia Drugs Market Research Report 2022
BUY CHAPTERS

Global Hemophilia Drugs Market Research Report 2025

Code: QYRE-Auto-34S10951
Report
September 2025
Pages:97
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
Baxalta
Bayer
CSL Behring
Pfizer Inc
Alnylam Pharmaceuticals
BioMarin
Catalyst Biosciences
Dimension Therapeutics
F.Hoffmann-La Roche
Grifols S A
Octapharma AG
Sangamo BioSciences
Spark Therapeutics
Swedish Orphan Biovitrum

Hemophilia Drugs Market Size

The global market for Hemophilia Drugs was valued at US$ 13820 million in the year 2024 and is projected to reach a revised size of US$ 18240 million by 2031, growing at a CAGR of 4.1% during the forecast period.

Hemophilia Drugs Market

Hemophilia Drugs Market

The hemophilia treatment drugs market is experiencing entry of a large number of new drugs in the market. Few of them have already arrived and other long lasting clotting factors and more promising drugs are on their way to get launched in this market. For instance, follow up data from phase I/II study of hemophilia medicine ‘Emicizumab’ by Roche has demonstrated promising results regarding safety and prophylactic efficiency in people with severe hemophilia A. Another example is of ‘Eloctate’ for type A and ‘Aprolix’ for type B hemophilia, respectively. These two newly arrived biogen products are opposed to commonly prescribe course of three infusions per week as they are longer-acting than traditional treatments and require only one to two infusions per week, due to their new mechanism of action.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Hemophilia Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Hemophilia Drugs.
The Hemophilia Drugs market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Hemophilia Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Hemophilia Drugs manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Scope of Hemophilia Drugs Market Report

Report Metric Details
Report Name Hemophilia Drugs Market
Accounted market size in year US$ 13820 million
Forecasted market size in 2031 US$ 18240 million
CAGR 4.1%
Base Year year
Forecasted years 2025 - 2031
Segment by Type
  • Hemophilia A
  • Inhibitors
  • Hemophilia B
  • Von Willebrand Disease
Segment by Application
  • Recombinant Therapies
  • Plasma-Derived Therapies
Consumption by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, Taiwan)
  • Southeast Asia (India)
  • Latin America (Mexico, Brazil)
By Company Baxalta, Bayer, CSL Behring, Pfizer, Alnylam Pharmaceuticals, BioMarin, Catalyst Biosciences, Dimension Therapeutics, F. Hoffmann-La Roche, Grifols, Octapharma, Sangamo Biosciences, Spark Therapeutics, Swedish Orphan Biovitrum
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Core Chapters

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Detailed analysis of Hemophilia Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 3: Sales, revenue of Hemophilia Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
  • Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
  • Chapter 9: The main points and conclusions of the report. 

FAQ for this report

How fast is Hemophilia Drugs Market growing?

Ans: The Hemophilia Drugs Market witnessing a CAGR of 4.1% during the forecast period 2025-2031.

What is the Hemophilia Drugs Market size in 2031?

Ans: The Hemophilia Drugs Market size in 2031 will be US$ 18240 million.

Who are the main players in the Hemophilia Drugs Market report?

Ans: The main players in the Hemophilia Drugs Market are Baxalta, Bayer, CSL Behring, Pfizer, Alnylam Pharmaceuticals, BioMarin, Catalyst Biosciences, Dimension Therapeutics, F. Hoffmann-La Roche, Grifols, Octapharma, Sangamo Biosciences, Spark Therapeutics, Swedish Orphan Biovitrum

What are the Application segmentation covered in the Hemophilia Drugs Market report?

Ans: The Applications covered in the Hemophilia Drugs Market report are Recombinant Therapies, Plasma-Derived Therapies

What are the Type segmentation covered in the Hemophilia Drugs Market report?

Ans: The Types covered in the Hemophilia Drugs Market report are Hemophilia A, Inhibitors, Hemophilia B, Von Willebrand Disease

1 Hemophilia Drugs Market Overview
1.1 Product Definition
1.2 Hemophilia Drugs by Type
1.2.1 Global Hemophilia Drugs Market Value Comparison by Type (2024 VS 2031)
1.2.2 Hemophilia A
1.2.3 Inhibitors
1.2.4 Hemophilia B
1.2.5 Von Willebrand Disease
1.3 Hemophilia Drugs by Application
1.3.1 Global Hemophilia Drugs Market Value by Application (2024 VS 2031)
1.3.2 Recombinant Therapies
1.3.3 Plasma-Derived Therapies
1.4 Global Hemophilia Drugs Market Size Estimates and Forecasts
1.4.1 Global Hemophilia Drugs Revenue 2020-2031
1.4.2 Global Hemophilia Drugs Sales 2020-2031
1.4.3 Global Hemophilia Drugs Market Average Price (2020-2031)
1.5 Assumptions and Limitations
2 Hemophilia Drugs Market Competition by Manufacturers
2.1 Global Hemophilia Drugs Sales Market Share by Manufacturers (2020-2025)
2.2 Global Hemophilia Drugs Revenue Market Share by Manufacturers (2020-2025)
2.3 Global Hemophilia Drugs Average Price by Manufacturers (2020-2025)
2.4 Global Key Players of Hemophilia Drugs, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Hemophilia Drugs, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Hemophilia Drugs, Product Type & Application
2.7 Global Key Manufacturers of Hemophilia Drugs, Date of Enter into This Industry
2.8 Global Hemophilia Drugs Market Competitive Situation and Trends
2.8.1 Global Hemophilia Drugs Market Concentration Rate
2.8.2 The Global 5 and 10 Largest Hemophilia Drugs Players Market Share by Revenue
2.8.3 Global Hemophilia Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Hemophilia Drugs Market Scenario by Region
3.1 Global Hemophilia Drugs Market Size by Region: 2020 Versus 2024 Versus 2031
3.2 Global Hemophilia Drugs Sales by Region: 2020-2031
3.2.1 Global Hemophilia Drugs Sales by Region: 2020-2025
3.2.2 Global Hemophilia Drugs Sales by Region: 2026-2031
3.3 Global Hemophilia Drugs Revenue by Region: 2020-2031
3.3.1 Global Hemophilia Drugs Revenue by Region: 2020-2025
3.3.2 Global Hemophilia Drugs Revenue by Region: 2026-2031
3.4 North America Hemophilia Drugs Market Facts & Figures by Country
3.4.1 North America Hemophilia Drugs Market Size by Country: 2020 VS 2024 VS 2031
3.4.2 North America Hemophilia Drugs Sales by Country (2020-2031)
3.4.3 North America Hemophilia Drugs Revenue by Country (2020-2031)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Hemophilia Drugs Market Facts & Figures by Country
3.5.1 Europe Hemophilia Drugs Market Size by Country: 2020 VS 2024 VS 2031
3.5.2 Europe Hemophilia Drugs Sales by Country (2020-2031)
3.5.3 Europe Hemophilia Drugs Revenue by Country (2020-2031)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Hemophilia Drugs Market Facts & Figures by Region
3.6.1 Asia Pacific Hemophilia Drugs Market Size by Region: 2020 VS 2024 VS 2031
3.6.2 Asia Pacific Hemophilia Drugs Sales by Region (2020-2031)
3.6.3 Asia Pacific Hemophilia Drugs Revenue by Region (2020-2031)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Hemophilia Drugs Market Facts & Figures by Country
3.7.1 Latin America Hemophilia Drugs Market Size by Country: 2020 VS 2024 VS 2031
3.7.2 Latin America Hemophilia Drugs Sales by Country (2020-2031)
3.7.3 Latin America Hemophilia Drugs Revenue by Country (2020-2031)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Hemophilia Drugs Market Facts & Figures by Country
3.8.1 Middle East and Africa Hemophilia Drugs Market Size by Country: 2020 VS 2024 VS 2031
3.8.2 Middle East and Africa Hemophilia Drugs Sales by Country (2020-2031)
3.8.3 Middle East and Africa Hemophilia Drugs Revenue by Country (2020-2031)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 U.A.E
4 Segment by Type
4.1 Global Hemophilia Drugs Sales by Type (2020-2031)
4.1.1 Global Hemophilia Drugs Sales by Type (2020-2025)
4.1.2 Global Hemophilia Drugs Sales by Type (2026-2031)
4.1.3 Global Hemophilia Drugs Sales Market Share by Type (2020-2031)
4.2 Global Hemophilia Drugs Revenue by Type (2020-2031)
4.2.1 Global Hemophilia Drugs Revenue by Type (2020-2025)
4.2.2 Global Hemophilia Drugs Revenue by Type (2026-2031)
4.2.3 Global Hemophilia Drugs Revenue Market Share by Type (2020-2031)
4.3 Global Hemophilia Drugs Price by Type (2020-2031)
5 Segment by Application
5.1 Global Hemophilia Drugs Sales by Application (2020-2031)
5.1.1 Global Hemophilia Drugs Sales by Application (2020-2025)
5.1.2 Global Hemophilia Drugs Sales by Application (2026-2031)
5.1.3 Global Hemophilia Drugs Sales Market Share by Application (2020-2031)
5.2 Global Hemophilia Drugs Revenue by Application (2020-2031)
5.2.1 Global Hemophilia Drugs Revenue by Application (2020-2025)
5.2.2 Global Hemophilia Drugs Revenue by Application (2026-2031)
5.2.3 Global Hemophilia Drugs Revenue Market Share by Application (2020-2031)
5.3 Global Hemophilia Drugs Price by Application (2020-2031)
6 Key Companies Profiled
6.1 Baxalta
6.1.1 Baxalta Company Information
6.1.2 Baxalta Description and Business Overview
6.1.3 Baxalta Hemophilia Drugs Sales, Revenue and Gross Margin (2020-2025)
6.1.4 Baxalta Hemophilia Drugs Product Portfolio
6.1.5 Baxalta Recent Developments/Updates
6.2 Bayer
6.2.1 Bayer Company Information
6.2.2 Bayer Description and Business Overview
6.2.3 Bayer Hemophilia Drugs Sales, Revenue and Gross Margin (2020-2025)
6.2.4 Bayer Hemophilia Drugs Product Portfolio
6.2.5 Bayer Recent Developments/Updates
6.3 CSL Behring
6.3.1 CSL Behring Company Information
6.3.2 CSL Behring Description and Business Overview
6.3.3 CSL Behring Hemophilia Drugs Sales, Revenue and Gross Margin (2020-2025)
6.3.4 CSL Behring Hemophilia Drugs Product Portfolio
6.3.5 CSL Behring Recent Developments/Updates
6.4 Pfizer
6.4.1 Pfizer Company Information
6.4.2 Pfizer Description and Business Overview
6.4.3 Pfizer Hemophilia Drugs Sales, Revenue and Gross Margin (2020-2025)
6.4.4 Pfizer Hemophilia Drugs Product Portfolio
6.4.5 Pfizer Recent Developments/Updates
6.5 Alnylam Pharmaceuticals
6.5.1 Alnylam Pharmaceuticals Company Information
6.5.2 Alnylam Pharmaceuticals Description and Business Overview
6.5.3 Alnylam Pharmaceuticals Hemophilia Drugs Sales, Revenue and Gross Margin (2020-2025)
6.5.4 Alnylam Pharmaceuticals Hemophilia Drugs Product Portfolio
6.5.5 Alnylam Pharmaceuticals Recent Developments/Updates
6.6 BioMarin
6.6.1 BioMarin Company Information
6.6.2 BioMarin Description and Business Overview
6.6.3 BioMarin Hemophilia Drugs Sales, Revenue and Gross Margin (2020-2025)
6.6.4 BioMarin Hemophilia Drugs Product Portfolio
6.6.5 BioMarin Recent Developments/Updates
6.7 Catalyst Biosciences
6.7.1 Catalyst Biosciences Company Information
6.7.2 Catalyst Biosciences Description and Business Overview
6.7.3 Catalyst Biosciences Hemophilia Drugs Sales, Revenue and Gross Margin (2020-2025)
6.7.4 Catalyst Biosciences Hemophilia Drugs Product Portfolio
6.7.5 Catalyst Biosciences Recent Developments/Updates
6.8 Dimension Therapeutics
6.8.1 Dimension Therapeutics Company Information
6.8.2 Dimension Therapeutics Description and Business Overview
6.8.3 Dimension Therapeutics Hemophilia Drugs Sales, Revenue and Gross Margin (2020-2025)
6.8.4 Dimension Therapeutics Hemophilia Drugs Product Portfolio
6.8.5 Dimension Therapeutics Recent Developments/Updates
6.9 F. Hoffmann-La Roche
6.9.1 F. Hoffmann-La Roche Company Information
6.9.2 F. Hoffmann-La Roche Description and Business Overview
6.9.3 F. Hoffmann-La Roche Hemophilia Drugs Sales, Revenue and Gross Margin (2020-2025)
6.9.4 F. Hoffmann-La Roche Hemophilia Drugs Product Portfolio
6.9.5 F. Hoffmann-La Roche Recent Developments/Updates
6.10 Grifols
6.10.1 Grifols Company Information
6.10.2 Grifols Description and Business Overview
6.10.3 Grifols Hemophilia Drugs Sales, Revenue and Gross Margin (2020-2025)
6.10.4 Grifols Hemophilia Drugs Product Portfolio
6.10.5 Grifols Recent Developments/Updates
6.11 Octapharma
6.11.1 Octapharma Company Information
6.11.2 Octapharma Description and Business Overview
6.11.3 Octapharma Hemophilia Drugs Sales, Revenue and Gross Margin (2020-2025)
6.11.4 Octapharma Hemophilia Drugs Product Portfolio
6.11.5 Octapharma Recent Developments/Updates
6.12 Sangamo Biosciences
6.12.1 Sangamo Biosciences Company Information
6.12.2 Sangamo Biosciences Description and Business Overview
6.12.3 Sangamo Biosciences Hemophilia Drugs Sales, Revenue and Gross Margin (2020-2025)
6.12.4 Sangamo Biosciences Hemophilia Drugs Product Portfolio
6.12.5 Sangamo Biosciences Recent Developments/Updates
6.13 Spark Therapeutics
6.13.1 Spark Therapeutics Company Information
6.13.2 Spark Therapeutics Description and Business Overview
6.13.3 Spark Therapeutics Hemophilia Drugs Sales, Revenue and Gross Margin (2020-2025)
6.13.4 Spark Therapeutics Hemophilia Drugs Product Portfolio
6.13.5 Spark Therapeutics Recent Developments/Updates
6.14 Swedish Orphan Biovitrum
6.14.1 Swedish Orphan Biovitrum Company Information
6.14.2 Swedish Orphan Biovitrum Description and Business Overview
6.14.3 Swedish Orphan Biovitrum Hemophilia Drugs Sales, Revenue and Gross Margin (2020-2025)
6.14.4 Swedish Orphan Biovitrum Hemophilia Drugs Product Portfolio
6.14.5 Swedish Orphan Biovitrum Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Hemophilia Drugs Industry Chain Analysis
7.2 Hemophilia Drugs Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Hemophilia Drugs Production Mode & Process Analysis
7.4 Hemophilia Drugs Sales and Marketing
7.4.1 Hemophilia Drugs Sales Channels
7.4.2 Hemophilia Drugs Distributors
7.5 Hemophilia Drugs Customer Analysis
8 Hemophilia Drugs Market Dynamics
8.1 Hemophilia Drugs Industry Trends
8.2 Hemophilia Drugs Market Drivers
8.3 Hemophilia Drugs Market Challenges
8.4 Hemophilia Drugs Market Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
FEATURED COMPANIES
Baxalta
Bayer
CSL Behring
Pfizer Inc
Alnylam Pharmaceuticals
BioMarin
Catalyst Biosciences
Dimension Therapeutics
F.Hoffmann-La Roche
Grifols S A
Octapharma AG
Sangamo BioSciences
Spark Therapeutics
Swedish Orphan Biovitrum
List of Tables
 Table 1. Global Hemophilia Drugs Market Value Comparison by Type (2024 VS 2031) & (US$ Million)
 Table 2. Global Hemophilia Drugs Market Value by Application (2024 VS 2031) & (US$ Million)
 Table 3. Global Hemophilia Drugs Market Competitive Situation by Manufacturers in 2024
 Table 4. Global Hemophilia Drugs Sales (K Units) of Key Manufacturers (2020-2025)
 Table 5. Global Hemophilia Drugs Sales Market Share by Manufacturers (2020-2025)
 Table 6. Global Hemophilia Drugs Revenue (US$ Million) by Manufacturers (2020-2025)
 Table 7. Global Hemophilia Drugs Revenue Share by Manufacturers (2020-2025)
 Table 8. Global Market Hemophilia Drugs Average Price (USD/Unit) of Key Manufacturers (2020-2025)
 Table 9. Global Key Players of Hemophilia Drugs, Industry Ranking, 2022 VS 2023 VS 2024
 Table 10. Global Key Manufacturers of Hemophilia Drugs, Manufacturing Sites & Headquarters
 Table 11. Global Key Manufacturers of Hemophilia Drugs, Product Type & Application
 Table 12. Global Key Manufacturers of Hemophilia Drugs, Date of Enter into This Industry
 Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
 Table 14. Global Hemophilia Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Hemophilia Drugs as of 2024)
 Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
 Table 16. Global Hemophilia Drugs Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 17. Global Hemophilia Drugs Sales by Region (2020-2025) & (K Units)
 Table 18. Global Hemophilia Drugs Sales Market Share by Region (2020-2025)
 Table 19. Global Hemophilia Drugs Sales by Region (2026-2031) & (K Units)
 Table 20. Global Hemophilia Drugs Sales Market Share by Region (2026-2031)
 Table 21. Global Hemophilia Drugs Revenue by Region (2020-2025) & (US$ Million)
 Table 22. Global Hemophilia Drugs Revenue Market Share by Region (2020-2025)
 Table 23. Global Hemophilia Drugs Revenue by Region (2026-2031) & (US$ Million)
 Table 24. Global Hemophilia Drugs Revenue Market Share by Region (2026-2031)
 Table 25. North America Hemophilia Drugs Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 26. North America Hemophilia Drugs Sales by Country (2020-2025) & (K Units)
 Table 27. North America Hemophilia Drugs Sales by Country (2026-2031) & (K Units)
 Table 28. North America Hemophilia Drugs Revenue by Country (2020-2025) & (US$ Million)
 Table 29. North America Hemophilia Drugs Revenue by Country (2026-2031) & (US$ Million)
 Table 30. Europe Hemophilia Drugs Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 31. Europe Hemophilia Drugs Sales by Country (2020-2025) & (K Units)
 Table 32. Europe Hemophilia Drugs Sales by Country (2026-2031) & (K Units)
 Table 33. Europe Hemophilia Drugs Revenue by Country (2020-2025) & (US$ Million)
 Table 34. Europe Hemophilia Drugs Revenue by Country (2026-2031) & (US$ Million)
 Table 35. Asia Pacific Hemophilia Drugs Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 36. Asia Pacific Hemophilia Drugs Sales by Region (2020-2025) & (K Units)
 Table 37. Asia Pacific Hemophilia Drugs Sales by Region (2026-2031) & (K Units)
 Table 38. Asia Pacific Hemophilia Drugs Revenue by Region (2020-2025) & (US$ Million)
 Table 39. Asia Pacific Hemophilia Drugs Revenue by Region (2026-2031) & (US$ Million)
 Table 40. Latin America Hemophilia Drugs Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 41. Latin America Hemophilia Drugs Sales by Country (2020-2025) & (K Units)
 Table 42. Latin America Hemophilia Drugs Sales by Country (2026-2031) & (K Units)
 Table 43. Latin America Hemophilia Drugs Revenue by Country (2020-2025) & (US$ Million)
 Table 44. Latin America Hemophilia Drugs Revenue by Country (2026-2031) & (US$ Million)
 Table 45. Middle East and Africa Hemophilia Drugs Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 46. Middle East and Africa Hemophilia Drugs Sales by Country (2020-2025) & (K Units)
 Table 47. Middle East and Africa Hemophilia Drugs Sales by Country (2026-2031) & (K Units)
 Table 48. Middle East and Africa Hemophilia Drugs Revenue by Country (2020-2025) & (US$ Million)
 Table 49. Middle East and Africa Hemophilia Drugs Revenue by Country (2026-2031) & (US$ Million)
 Table 50. Global Hemophilia Drugs Sales (K Units) by Type (2020-2025)
 Table 51. Global Hemophilia Drugs Sales (K Units) by Type (2026-2031)
 Table 52. Global Hemophilia Drugs Sales Market Share by Type (2020-2025)
 Table 53. Global Hemophilia Drugs Sales Market Share by Type (2026-2031)
 Table 54. Global Hemophilia Drugs Revenue (US$ Million) by Type (2020-2025)
 Table 55. Global Hemophilia Drugs Revenue (US$ Million) by Type (2026-2031)
 Table 56. Global Hemophilia Drugs Revenue Market Share by Type (2020-2025)
 Table 57. Global Hemophilia Drugs Revenue Market Share by Type (2026-2031)
 Table 58. Global Hemophilia Drugs Price (USD/Unit) by Type (2020-2025)
 Table 59. Global Hemophilia Drugs Price (USD/Unit) by Type (2026-2031)
 Table 60. Global Hemophilia Drugs Sales (K Units) by Application (2020-2025)
 Table 61. Global Hemophilia Drugs Sales (K Units) by Application (2026-2031)
 Table 62. Global Hemophilia Drugs Sales Market Share by Application (2020-2025)
 Table 63. Global Hemophilia Drugs Sales Market Share by Application (2026-2031)
 Table 64. Global Hemophilia Drugs Revenue (US$ Million) by Application (2020-2025)
 Table 65. Global Hemophilia Drugs Revenue (US$ Million) by Application (2026-2031)
 Table 66. Global Hemophilia Drugs Revenue Market Share by Application (2020-2025)
 Table 67. Global Hemophilia Drugs Revenue Market Share by Application (2026-2031)
 Table 68. Global Hemophilia Drugs Price (USD/Unit) by Application (2020-2025)
 Table 69. Global Hemophilia Drugs Price (USD/Unit) by Application (2026-2031)
 Table 70. Baxalta Company Information
 Table 71. Baxalta Description and Business Overview
 Table 72. Baxalta Hemophilia Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 73. Baxalta Hemophilia Drugs Product
 Table 74. Baxalta Recent Developments/Updates
 Table 75. Bayer Company Information
 Table 76. Bayer Description and Business Overview
 Table 77. Bayer Hemophilia Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 78. Bayer Hemophilia Drugs Product
 Table 79. Bayer Recent Developments/Updates
 Table 80. CSL Behring Company Information
 Table 81. CSL Behring Description and Business Overview
 Table 82. CSL Behring Hemophilia Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 83. CSL Behring Hemophilia Drugs Product
 Table 84. CSL Behring Recent Developments/Updates
 Table 85. Pfizer Company Information
 Table 86. Pfizer Description and Business Overview
 Table 87. Pfizer Hemophilia Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 88. Pfizer Hemophilia Drugs Product
 Table 89. Pfizer Recent Developments/Updates
 Table 90. Alnylam Pharmaceuticals Company Information
 Table 91. Alnylam Pharmaceuticals Description and Business Overview
 Table 92. Alnylam Pharmaceuticals Hemophilia Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 93. Alnylam Pharmaceuticals Hemophilia Drugs Product
 Table 94. Alnylam Pharmaceuticals Recent Developments/Updates
 Table 95. BioMarin Company Information
 Table 96. BioMarin Description and Business Overview
 Table 97. BioMarin Hemophilia Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 98. BioMarin Hemophilia Drugs Product
 Table 99. BioMarin Recent Developments/Updates
 Table 100. Catalyst Biosciences Company Information
 Table 101. Catalyst Biosciences Description and Business Overview
 Table 102. Catalyst Biosciences Hemophilia Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 103. Catalyst Biosciences Hemophilia Drugs Product
 Table 104. Catalyst Biosciences Recent Developments/Updates
 Table 105. Dimension Therapeutics Company Information
 Table 106. Dimension Therapeutics Description and Business Overview
 Table 107. Dimension Therapeutics Hemophilia Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 108. Dimension Therapeutics Hemophilia Drugs Product
 Table 109. Dimension Therapeutics Recent Developments/Updates
 Table 110. F. Hoffmann-La Roche Company Information
 Table 111. F. Hoffmann-La Roche Description and Business Overview
 Table 112. F. Hoffmann-La Roche Hemophilia Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 113. F. Hoffmann-La Roche Hemophilia Drugs Product
 Table 114. F. Hoffmann-La Roche Recent Developments/Updates
 Table 115. Grifols Company Information
 Table 116. Grifols Description and Business Overview
 Table 117. Grifols Hemophilia Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 118. Grifols Hemophilia Drugs Product
 Table 119. Grifols Recent Developments/Updates
 Table 120. Octapharma Company Information
 Table 121. Octapharma Description and Business Overview
 Table 122. Octapharma Hemophilia Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 123. Octapharma Hemophilia Drugs Product
 Table 124. Octapharma Recent Developments/Updates
 Table 125. Sangamo Biosciences Company Information
 Table 126. Sangamo Biosciences Description and Business Overview
 Table 127. Sangamo Biosciences Hemophilia Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 128. Sangamo Biosciences Hemophilia Drugs Product
 Table 129. Sangamo Biosciences Recent Developments/Updates
 Table 130. Spark Therapeutics Company Information
 Table 131. Spark Therapeutics Description and Business Overview
 Table 132. Spark Therapeutics Hemophilia Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 133. Spark Therapeutics Hemophilia Drugs Product
 Table 134. Spark Therapeutics Recent Developments/Updates
 Table 135. Swedish Orphan Biovitrum Company Information
 Table 136. Swedish Orphan Biovitrum Description and Business Overview
 Table 137. Swedish Orphan Biovitrum Hemophilia Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 138. Swedish Orphan Biovitrum Hemophilia Drugs Product
 Table 139. Swedish Orphan Biovitrum Recent Developments/Updates
 Table 140. Key Raw Materials Lists
 Table 141. Raw Materials Key Suppliers Lists
 Table 142. Hemophilia Drugs Distributors List
 Table 143. Hemophilia Drugs Customers List
 Table 144. Hemophilia Drugs Market Trends
 Table 145. Hemophilia Drugs Market Drivers
 Table 146. Hemophilia Drugs Market Challenges
 Table 147. Hemophilia Drugs Market Restraints
 Table 148. Research Programs/Design for This Report
 Table 149. Key Data Information from Secondary Sources
 Table 150. Key Data Information from Primary Sources
 Table 151. Authors List of This Report


List of Figures
 Figure 1. Product Picture of Hemophilia Drugs
 Figure 2. Global Hemophilia Drugs Market Value Comparison by Type (2020-2031) & (US$ Million)
 Figure 3. Global Hemophilia Drugs Market Share by Type: 2024 & 2031
 Figure 4. Hemophilia A Product Picture
 Figure 5. Inhibitors Product Picture
 Figure 6. Hemophilia B Product Picture
 Figure 7. Von Willebrand Disease Product Picture
 Figure 8. Global Hemophilia Drugs Market Value by Application (2020-2031) & (US$ Million)
 Figure 9. Global Hemophilia Drugs Market Share by Application: 2024 & 2031
 Figure 10. Recombinant Therapies
 Figure 11. Plasma-Derived Therapies
 Figure 12. Global Hemophilia Drugs Revenue, (US$ Million), 2020 VS 2024 VS 2031
 Figure 13. Global Hemophilia Drugs Market Size (2020-2031) & (US$ Million)
 Figure 14. Global Hemophilia Drugs Sales (2020-2031) & (K Units)
 Figure 15. Global Hemophilia Drugs Average Price (USD/Unit) & (2020-2031)
 Figure 16. Hemophilia Drugs Report Years Considered
 Figure 17. Hemophilia Drugs Sales Share by Manufacturers in 2024
 Figure 18. Global Hemophilia Drugs Revenue Share by Manufacturers in 2024
 Figure 19. Global 5 and 10 Largest Hemophilia Drugs Players: Market Share by Revenue in Hemophilia Drugs in 2024
 Figure 20. Hemophilia Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
 Figure 21. Global Hemophilia Drugs Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Figure 22. North America Hemophilia Drugs Sales Market Share by Country (2020-2031)
 Figure 23. North America Hemophilia Drugs Revenue Market Share by Country (2020-2031)
 Figure 24. U.S. Hemophilia Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 25. Canada Hemophilia Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 26. Europe Hemophilia Drugs Sales Market Share by Country (2020-2031)
 Figure 27. Europe Hemophilia Drugs Revenue Market Share by Country (2020-2031)
 Figure 28. Germany Hemophilia Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 29. France Hemophilia Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 30. U.K. Hemophilia Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 31. Italy Hemophilia Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 32. Russia Hemophilia Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 33. Asia Pacific Hemophilia Drugs Sales Market Share by Region (2020-2031)
 Figure 34. Asia Pacific Hemophilia Drugs Revenue Market Share by Region (2020-2031)
 Figure 35. China Hemophilia Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 36. Japan Hemophilia Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 37. South Korea Hemophilia Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 38. India Hemophilia Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 39. Australia Hemophilia Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 40. Taiwan Hemophilia Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 41. Indonesia Hemophilia Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 42. Thailand Hemophilia Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 43. Malaysia Hemophilia Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 44. Philippines Hemophilia Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 45. Latin America Hemophilia Drugs Sales Market Share by Country (2020-2031)
 Figure 46. Latin America Hemophilia Drugs Revenue Market Share by Country (2020-2031)
 Figure 47. Mexico Hemophilia Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 48. Brazil Hemophilia Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 49. Argentina Hemophilia Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 50. Middle East and Africa Hemophilia Drugs Sales Market Share by Country (2020-2031)
 Figure 51. Middle East and Africa Hemophilia Drugs Revenue Market Share by Country (2020-2031)
 Figure 52. Turkey Hemophilia Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 53. Saudi Arabia Hemophilia Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 54. U.A.E Hemophilia Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 55. Global Sales Market Share of Hemophilia Drugs by Type (2020-2031)
 Figure 56. Global Revenue Market Share of Hemophilia Drugs by Type (2020-2031)
 Figure 57. Global Hemophilia Drugs Price (USD/Unit) by Type (2020-2031)
 Figure 58. Global Sales Market Share of Hemophilia Drugs by Application (2020-2031)
 Figure 59. Global Revenue Market Share of Hemophilia Drugs by Application (2020-2031)
 Figure 60. Global Hemophilia Drugs Price (USD/Unit) by Application (2020-2031)
 Figure 61. Hemophilia Drugs Value Chain
 Figure 62. Channels of Distribution (Direct Vs Distribution)
 Figure 63. Bottom-up and Top-down Approaches for This Report
 Figure 64. Data Triangulation
 Figure 65. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Accenture

SIMILAR REPORTS

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions